Combined effects of treatment with trientine, a copper-chelating agent, and x-irradiation on tumor growth in transplantation model of a murine fibrosarcoma.
Combined effects of treatment with trientine, a copper-chelating agent, and X-irradiation on development of fibrosarcoma using a murine transplantation model in vivo and on cellular survival in vitro were examined. Copper contents in the tumors and serum of trientine-treated mice were significantly lower than those of untreated mice. The tumor volumes of mouse fibrosarcoma QRsp-11 cells increased more slowly in the trientine-treated and the X-irradiated mice than in the control mice from 10 to 24 days postinoculation. The extent of inhibition of tumor growth by X-irradiation at 3 Gy was similar to that obtained by treatment with trientine. A combination of trientine and X-irradiation at 3 Gy showed inhibitory effects on tumor growth similar to those obtained by X-irradiation at 6 Gy. The results showed that trientine and X-irradiation interacted additively in inhibition of tumor growth. When QRsp-11 cells and mouse and bovine endothelial cells were treated with trientine after X-irradiation, the surviving fractions of the cells with combined treatments were essentially consistent with the products of the surviving fractions of trientine-treated cells and those of X-irradiated cells. When the cells were pretreated with trientine and X-irradiated, the surviving fractions of the pretreated cells were lower than those of cells without treatment.
Hayashi
Masanobu
M
Department of Veterinary Radiology, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan. hayashi@rakuno.ac.jp
Hirai
Ryou
R
Ishihara
Yuusuke
Y
Horiguchi
Noboru
N
Endoh
Daiji
D
Okui
Toyo
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use*; D005354:Fibrosarcoma / Q000628:therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000628:therapy*; D013047:Specific Pathogen-Free Organisms; D013997:Time Factors; D014266:Trientine / Q000627:therapeutic use*; D014964:X-Ray Therapy; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D002614:Chelating Agents; D014266:Trientine